Images

[From BioPharmaDive] “GlaxoSmithKline subsidiary ViiV Healthcare believes its portfolio of HIV medications will be competitive as treatment for the virus enters an era of two-drug regimens. So far, however, the company’s first doublet has performed modestly on the market compared to a key rival’s three-drug regimen.” For more, click here.

[From Inside Philanthropy] “December 1, the 30th anniversary of the first World AIDS Day, offered a moment take stock of the ongoing battle against an epidemic that’s killed 35 million people since the 1980s. The good news is that antiretroviral therapy has transformed HIV from a nearly always fatal infection into a manageable chronic condition.

[From aidsmap, Oct 19, 2018] “An HIV-negative child received a liver transplant from its HIV-positive mother and now appears to have no evidence of HIV infection apart from a very weak antibody response, despite extensive testing for the virus, South African researchers report in the journal AIDS. Researchers cannot decide whether the child has cleared HIV

[From SciDevNet, Oct 22, 2018] “Over the last two decades, the world has made huge gains in the control of the HIVepidemic. But now, these gains are at risk of stalling.” For more, click here.

[From NBC News, Oct 15, 2018] “When the AIDS plague finally took hold in the U.S., it surged through communities that the straight world preferred not to see. It took a few tries. The virus lurked in tropical regions of central Africa, and made several incursions into the American continent before becoming a global pandemic. HIV